Bioresorbable vascular scaffold implantation for severely calcified lesions after excimer laser lesion preparation

S Mitomo, RJ Jabbour, A Latib, A Colombo

Research output: Contribution to journalArticle

Abstract

Bioresorbable vascular scaffolds (Absorb BVS, Abbott Vascular, Santa Clara, CA) temporarily elute antiproliferative drugs and provide vessel support, which then subsequently resorb to allow restoration of normal vessel function and architecture. To attain the best possible results with BVS, a dedicated implantation technique (PSP: adequate lesion preparation, proper sizing, postdilatation) is considered mandatory, and calcified lesions are one of the most challenging lesion subsets for BVS implantation. In five cases with severe calcifications refractory to balloon predilatation, we performed excimer laser catheter ablation (ELCA: Turbo Elite catheter; Spectranetics Corporation, Colorado Springs, CO, USA), which facilitated adequate lesion expansion with high-pressure noncompliant balloon inflation and BVS implantation. During the follow-up period (481 days [interquartile range: 445–579]), all patients continued dual antiplatelet therapy (DAPT) and there were no cases of cardiac death, myocardial infarction, or scaffold thrombosis. For treatment of severely calcified lesions with bioresorbable scaffolds, ELCA could be considered an effective potential strategy. After the procedure, prolonged DAPT was prescribed. © 2018 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)1283-1288
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Volume92
Issue number7
DOIs
Publication statusPublished - 2018

Fingerprint

Excimer Lasers
Blood Vessels
Catheter Ablation
Economic Inflation
Laser Therapy
Carbon Monoxide
Thrombosis
Therapeutics
Catheters
Myocardial Infarction
Pressure
Pharmaceutical Preparations

Cite this

Bioresorbable vascular scaffold implantation for severely calcified lesions after excimer laser lesion preparation. / Mitomo, S; Jabbour, RJ; Latib, A; Colombo, A.

In: Catheterization and Cardiovascular Interventions, Vol. 92, No. 7, 2018, p. 1283-1288.

Research output: Contribution to journalArticle

@article{3193a8ef64184a629427546e04153069,
title = "Bioresorbable vascular scaffold implantation for severely calcified lesions after excimer laser lesion preparation",
abstract = "Bioresorbable vascular scaffolds (Absorb BVS, Abbott Vascular, Santa Clara, CA) temporarily elute antiproliferative drugs and provide vessel support, which then subsequently resorb to allow restoration of normal vessel function and architecture. To attain the best possible results with BVS, a dedicated implantation technique (PSP: adequate lesion preparation, proper sizing, postdilatation) is considered mandatory, and calcified lesions are one of the most challenging lesion subsets for BVS implantation. In five cases with severe calcifications refractory to balloon predilatation, we performed excimer laser catheter ablation (ELCA: Turbo Elite catheter; Spectranetics Corporation, Colorado Springs, CO, USA), which facilitated adequate lesion expansion with high-pressure noncompliant balloon inflation and BVS implantation. During the follow-up period (481 days [interquartile range: 445–579]), all patients continued dual antiplatelet therapy (DAPT) and there were no cases of cardiac death, myocardial infarction, or scaffold thrombosis. For treatment of severely calcified lesions with bioresorbable scaffolds, ELCA could be considered an effective potential strategy. After the procedure, prolonged DAPT was prescribed. {\circledC} 2018 Wiley Periodicals, Inc.",
author = "S Mitomo and RJ Jabbour and A Latib and A Colombo",
year = "2018",
doi = "10.1002/ccd.27704",
language = "English",
volume = "92",
pages = "1283--1288",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Bioresorbable vascular scaffold implantation for severely calcified lesions after excimer laser lesion preparation

AU - Mitomo, S

AU - Jabbour, RJ

AU - Latib, A

AU - Colombo, A

PY - 2018

Y1 - 2018

N2 - Bioresorbable vascular scaffolds (Absorb BVS, Abbott Vascular, Santa Clara, CA) temporarily elute antiproliferative drugs and provide vessel support, which then subsequently resorb to allow restoration of normal vessel function and architecture. To attain the best possible results with BVS, a dedicated implantation technique (PSP: adequate lesion preparation, proper sizing, postdilatation) is considered mandatory, and calcified lesions are one of the most challenging lesion subsets for BVS implantation. In five cases with severe calcifications refractory to balloon predilatation, we performed excimer laser catheter ablation (ELCA: Turbo Elite catheter; Spectranetics Corporation, Colorado Springs, CO, USA), which facilitated adequate lesion expansion with high-pressure noncompliant balloon inflation and BVS implantation. During the follow-up period (481 days [interquartile range: 445–579]), all patients continued dual antiplatelet therapy (DAPT) and there were no cases of cardiac death, myocardial infarction, or scaffold thrombosis. For treatment of severely calcified lesions with bioresorbable scaffolds, ELCA could be considered an effective potential strategy. After the procedure, prolonged DAPT was prescribed. © 2018 Wiley Periodicals, Inc.

AB - Bioresorbable vascular scaffolds (Absorb BVS, Abbott Vascular, Santa Clara, CA) temporarily elute antiproliferative drugs and provide vessel support, which then subsequently resorb to allow restoration of normal vessel function and architecture. To attain the best possible results with BVS, a dedicated implantation technique (PSP: adequate lesion preparation, proper sizing, postdilatation) is considered mandatory, and calcified lesions are one of the most challenging lesion subsets for BVS implantation. In five cases with severe calcifications refractory to balloon predilatation, we performed excimer laser catheter ablation (ELCA: Turbo Elite catheter; Spectranetics Corporation, Colorado Springs, CO, USA), which facilitated adequate lesion expansion with high-pressure noncompliant balloon inflation and BVS implantation. During the follow-up period (481 days [interquartile range: 445–579]), all patients continued dual antiplatelet therapy (DAPT) and there were no cases of cardiac death, myocardial infarction, or scaffold thrombosis. For treatment of severely calcified lesions with bioresorbable scaffolds, ELCA could be considered an effective potential strategy. After the procedure, prolonged DAPT was prescribed. © 2018 Wiley Periodicals, Inc.

U2 - 10.1002/ccd.27704

DO - 10.1002/ccd.27704

M3 - Article

VL - 92

SP - 1283

EP - 1288

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 7

ER -